The $100M liquidity commitment and Rain's top-3 positioning are positive catalysts for Enlivex's treasury strategy, but the stock's correlation with RAIN token price and the highly speculative nature of prediction markets warrant caution. Monitor RAIN token price action and any further liquidity commitments or exchange listings that could validate the treasury thesis.
Price Chart
Executive Summary
Enlivex issued a press release commenting on the Rain Foundation's $100M liquidity commitment to the Rain prediction markets protocol, which positions Rain as the third-largest prediction market globally. Enlivex disclosed it holds 79.6 billion RAIN tokens valued at ~$919M and an option to acquire up to 271.4 billion additional RAIN tokens at $0.0033/token, with an intrinsic value of $2.23B as of May 26, 2026.
Key Facts
- Rain Foundation announced a $100M liquidity commitment ($50M USDT + $50M RAIN tokens) to Rain's prediction markets protocol.
- Rain is now positioned as the third-largest prediction market protocol globally by TVL, behind Polymarket (~$450M) and Kalshi.
- As of May 26, 2026, Enlivex held 79,568,550,005 RAIN tokens valued at approximately $919 million.
- Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation at $0.0033/token, expiring Dec. 31, 2027, with an intrinsic value of $2.23 billion as of May 26, 2026.
- The additional liquidity is expected to support increased prediction market activity ahead of the FIFA World Cup Soccer tournament.
Financial Impact
Enlivex's RAIN token holdings valued at ~$919M represent a significant portion of its $165M market cap; the option's $2.23B intrinsic value is ~13.5x market cap, creating substantial potential upside if exercised.
Risk Factors
- RAIN token price is highly volatile and may not sustain current valuation levels.
- The option to acquire additional RAIN tokens is contingent on market conditions and may expire worthless.
- Enlivex's stock price may be correlated with RAIN token liquidity and price, introducing crypto-specific risk.
- No clinical or revenue-generating operational updates were provided; the company remains a pre-revenue clinical-stage biotech with a novel treasury strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061243 |
| Document: ea0292240-6k_enlivex.htm | 0001213900-26-061243 |
| Document: 0001213900-26-061243-index-headers.html | 0001213900-26-061243 |
| Document: 0001213900-26-061243-index.html | 0001213900-26-061243 |
| Document: 0001213900-26-061243.txt | 0001213900-26-061243 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (−1379.12%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.56 (+398.99%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.56 (+296.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.56 (+62.33%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.56 (+31.53%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.56 (+13.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers